Syndax Reports Strong Q1 Revenue Growth, Reduced Loss, and Path to Profitability
SNDX has more than doubled off its 52-week low of $8.58.
Summary
Syndax Pharmaceuticals announced robust first-quarter 2026 financial results, featuring significant revenue growth driven by its key products, a substantial reduction in net loss, and a clear outlook towards achieving profitability.
Key Events · Earnings and Guidance · SNDX
-
Exceptional Revenue Growth
Total revenue for Q1 2026 reached $64.9 million, a 224% increase year-over-year, driven by strong sales of Revuforj ($48.9M) and Niktimvo collaboration revenue ($15.9M).
-
Significant Reduction in Net Loss
The company reported a net loss of $42.7 million ($0.48 per share) for Q1 2026, a substantial improvement from $84.8 million ($0.98 per share) in the prior year period.
-
Path to Profitability
Syndax expects its current cash, anticipated product revenue, and collaboration revenue to enable the company to reach profitability, supported by a stable operating expense base.
-
Robust Pipeline Progress
Multiple clinical milestones are anticipated in 2026, including new data for Revuforj across various acute leukemia settings and topline Phase 2 data for Niktimvo in Idiopathic Pulmonary Fibrosis (IPF) and newly diagnosed chronic GVHD.
Analysis · SNDX · Life Sciences
The filing highlights exceptional commercial performance for Revuforj and Niktimvo, with total revenue increasing 224% year-over-year. The company nearly halved its net loss compared to the prior year, demonstrating strong operational leverage and progress towards financial sustainability. With a healthy cash balance and stable expense outlook, Syndax projects reaching profitability, a critical milestone for a commercial-stage biopharmaceutical company. Additionally, the report provides positive updates on its clinical pipeline, including upcoming data readouts for both approved therapies in new indications and ongoing pivotal trials, reinforcing long-term growth prospects.
At the time of this filing, SNDX was trading at $20.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $8.58 to $25.59. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.